Markets ▾
Subscribe

BAF NEWS

BAF NEWS

Latest News

Latest

Wegovy 7.2 mg FDA filing: Faster review, bigger weight loss, and the next deadlines

The Wegovy 7.2 mg FDA filing marks Novo Nordisk's bid to introduce a higher once-weekly dose for adults with obesity, aiming for faster review under the FDA's accelerated pilot program. The application builds on STEP UP trial data, showing greater average weight loss, and could lead to a decision within 1–2 months if accepted.
  • No Comments

Meta Google TPU deal 2027: Inside the talks to diversify AI chips

The Meta Google TPU deal 2027 refers to ongoing talks for Meta to use Google’s custom TPUs in its data centers, potentially starting with Google Cloud TPU rentals before on-premises deployment by 2027. This move aims to reduce Meta’s reliance on Nvidia, signaling a shift in the AI chip market landscape.
  • No Comments

2027 Medicare price for Ozempic set at $274 as CMS finalizes 15 drug prices

The 2027 Medicare price for Ozempic will be $274 per month, as set by CMS under new negotiated caps for 15 widely used drugs. This Maximum Fair Price, effective January 1, 2027, aims to reduce costs for Medicare beneficiaries and the federal government, with projected savings of up to $12 billion compared to 2024 spending.
  • No Comments

Meta Google TPU deal 2025: Stocks, timeline, and what it means for AI chips

The Meta Google TPU deal 2025 could see Meta deploying Google’s TPUs in its data centers from 2027 and renting TPUs via Google Cloud as early as 2026. This potential agreement may shift AI chip market dynamics, impacting Nvidia and Alphabet stocks, and highlights the growing competition between Google TPUs and Nvidia GPUs.
  • No Comments

October 2025 Witkoff Kremlin call transcript: White House defends envoy as leak shapes Trump–Putin push

The October 2025 Witkoff Kremlin call transcript is now central to the White House’s defense of Steve Witkoff amid mounting criticism. The transcript details discussions on a Ukraine peace plan, including potential territorial concessions, and has sparked debate over U.S. negotiation strategy and its implications for ongoing Russia-Ukraine talks.
  • No Comments

Atlanta opens downtown government-funded supermarket: Inside Azalea Fresh Market’s public-private test

Atlanta opens downtown government-funded supermarket with the debut of Azalea Fresh Market, a 20,000-square-foot store operated by Savi Provisions. Supported by $8 million in city funding, this initiative aims to provide affordable groceries downtown, test a public-private model, and address food access gaps in underserved Atlanta neighborhoods.
  • No Comments

Oil prices recover Nov 26 from one-month lows: rate bets steady Brent, WTI

Oil prices recover Nov 26 after falling to one-month lows, with Brent and WTI edging higher as traders weigh rate-cut expectations against ongoing geopolitical and supply risks. The article analyzes the factors behind the modest rebound, including Ukraine peace talks, U.S. inventory data, and medium-term oversupply forecasts.
  • No Comments

November 2025 gold rally nears two‑week high as Fed cut bets firm

The November 2025 gold rally saw spot prices climb to a near two-week high, driven by rising fed rate cut bets December and dovish Federal Reserve commentary. Market-implied odds for a December rate cut surged, supporting bullion demand, while softer U.S. data and a weaker dollar added momentum to the rally.
  • No Comments

RBNZ cuts OCR to 2.25% as easing cycle extends into 2026

RBNZ cuts OCR to 2.25% as the central bank extends its easing cycle to support New Zealand’s fragile recovery. The decision, made by a 5–1 monetary policy committee vote, reflects ongoing disinflation and a cautious, data-dependent approach, with inflation projected to reach 2% by mid-2026.
  • No Comments

November 2025 ACA subsidies extension: where talks stand and what’s in the draft

The November 2025 ACA subsidies extension is under intense negotiation, with the White House proposing a two-year plan and Republicans largely opposed. The draft would alter eligibility and premium structures, and if no deal is reached, enhanced premium tax credits will expire December 31, potentially doubling costs for many enrollees.
  • No Comments

Trending

Bayer OCEANIC-STROKE results November 2025: asundexian hits efficacy and safety marks
Bayer OCEANIC-STROKE results November 2025 confirm that the Phase III trial of asundexian met its primary efficacy and safety endpoints in secondary stroke prevention. The topline data show reduced ischemic stroke risk without increased major bleeding, marking a first-in-class milestone for factor XIa inhibitors and prompting positive market reaction.
Amycretin phase 2 results 2025: Novo Nordisk posts double-digit weight loss and HbA1c gains
The amycretin phase 2 results 2025 show that Novo Nordisk’s dual GLP-1 and amylin agonist achieved up to 14.5% weight loss and significant HbA1c reductions in adults with type 2 diabetes over 36 weeks. Both weekly injection and daily oral regimens were well tolerated, supporting advancement to phase 3 trials in 2026.
Untitled Post
This article examines the December 2025 Fed rate cut odds, providing an analysis of current market expectations and economic indicators that could influence the Federal Reserve's decision. It offers insights into how these odds are calculated and what they may signal for investors and the broader economy.

Stay in the loop